Processing

Please wait...

Settings

Settings

1. WO1996003426 - HUMAN SERUM ALBUMIN-PORPHYRIN COMPLEXES WITH THE ABILITY TO BIND OXYGEN AND THERAPEUTIC USES THEREOF

Publication Number WO/1996/003426
Publication Date 08.02.1996
International Application No. PCT/US1995/008479
International Filing Date 07.07.1995
Chapter 2 Demand Filed 20.02.1996
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/765 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
76Albumins
765Serum albumin, e.g. HSA
C07K 14/795 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
795Porphyrin- or corrin-ring-containing peptides
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/765
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
76Albumins
765Serum albumin, e.g. HSA
C07K 14/795
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
795Porphyrin- or corrin-ring-containing peptides
Y02A 50/411
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
38Medical treatment of vector-borne diseases characterised by the agent
408the vector-borne disease being caused by a protozoa
411of the genus Plasmodium, i.e. Malaria
Y10S 530/83
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
530Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
827Proteins from mammals or birds
829Blood
83Plasma; serum
Applicants
  • DUKE UNIVERSITY [US/US]; 001 Allen Building Durham, NC 27706, US
Inventors
  • BONAVENTURA, Joseph; US
Agents
  • FLINTOFT, Gerald, G. ; Pennie & Edmonds 1155 Avenue of the Americas New York, NY 10036, US
Priority Data
279,37122.07.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HUMAN SERUM ALBUMIN-PORPHYRIN COMPLEXES WITH THE ABILITY TO BIND OXYGEN AND THERAPEUTIC USES THEREOF
(FR) COMPLEXES DE SERUMALBUMINE HUMAINE-PORPHYRINE POUVANT FIXER L'OXYGENE ET LEURS UTILISATIONS THERAPEUTIQUES
Abstract
(EN)
The invention is directed to human serum albumin-porphyrin (HSA-P) complexes which are capable of reversible oxygen binding and their uses. These complexes may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or in applications requiring plasma expanders. Methods for the production of these complexes are provided. In a specific example, HSA-P complexes are shown to exhibit reversible oxygen binding. In another example, the HSA-P complex does not exhibit appreciable vasoactivity.
(FR)
La présente invention concerne des complexes de sérumalbumine humaine-porphyrine (HSA-P) capables de fixer l'oxygène de manière réversible et leurs utilisations. Ces complexes peuvent s'utiliser dans des applications nécessitant des transporteurs physiologiques de l'oxygène comme dans les solutions de succédané du sang, ou dans des applications nécessitant des succédanées du plasma. L'invention concerne des procédés de production de ces complexes. Dans un exemple particulier, est mise en évidence la capacité des complexes HSA-P de fixer l'oxygène de manière réversible. Dans un autre exemple, le complexe HSA-P ne fait pas preuve d'une vasoactivité appréciable.
Latest bibliographic data on file with the International Bureau